A Phase 1, Multicenter, Open-Label, Single-Arm, Multiple Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Natalizumab in Pediatric Subjects with Relapsing Remitting Multiple Sclerosis
Phase of Trial: Phase I
Latest Information Update: 09 Jun 2015
Price : $35 *
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- Sponsors Biogen Idec
- 18 Jan 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 18 Aug 2014 Planned End Date changed from 1 Sep 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
- 18 Aug 2014 Planned primary completion date changed from 1 Sep 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov record.